

**IN THE UNITED STATES DISTRICT COURT  
FOR THE NORTHERN DISTRICT OF TEXAS  
DALLAS DIVISION**

In re:

Eiger BioPharmaceuticals, Inc., et al.,

Debtors.

---

Innovatus Life Sciences Lending Fund I, LP,

Appellant,

v.

Eiger BioPharmaceuticals, Inc., et al.,

Appellees.

Case No. 3:24-cv-02259-B

**JOINT STIPULATION OF DISMISSAL**

Pursuant to Federal Rule of Bankruptcy Procedure 8023(a), Appellant Innovatus Life Sciences Lending Fund I, LP and Appellees Eiger Biopharmaceuticals, Inc. and its affiliated debtors (collectively, the “Debtors”) stipulate and agree as follows:

1. The above-captioned bankruptcy appeal is hereby dismissed with prejudice.
2. Each party will bear its own costs subject to the Appellant’s right to payment or reimbursement of its costs in accordance with paragraph 30 of the *Order Approving the Debtors’ Amended Disclosure Statement and Confirming the Fifth Amended Joint Plan of Liquidation of Eiger Biopharmaceuticals, Inc. and its Debtor Affiliates* [Bankr. Docket No. 639] entered in the above-captioned bankruptcy cases.
3. There are no outstanding court fees.



Dated: September 10, 2024

Respectfully submitted,

/s/ Thomas R. Califano

Thomas R. Califano  
TX State Bar No. 24122825  
SIDLEY AUSTIN LLP  
787 Seventh Avenue  
New York, NY 10019  
Telephone: (212) 839-5300  
Facsimile: (212) 839-5599  
Email: tom.califano@sidley.com

ATTORNEYS FOR THE  
DEBTORS AND APPELLEES

/s/ Jeff P. Prostok

Jeff P. Prostok  
TX State Bar No. 16352500  
Emily S. Chou  
TX State Bar No. 24006997  
FORSHEY & PROSTOK LLP  
777 Main St., Suite 1550  
Fort Worth, TX 76102  
Telephone: 817-877-8855  
Facsimile: 817-877-4151  
Email: jprostok@forsheyprostok.com  
echou@forsheyprostok.com

ATTORNEYS FOR INNOVATUS LIFE  
SCIENCES LENDING FUND I, LP,  
APPELLANT

**CERTIFICATE OF SERVICE**

The undersigned hereby certifies that a copy of the foregoing instrument has been served on all parties and counsel of record in compliance with the Federal Rules of Civil Procedure via the Court's CM/ECF on this 10th day of September 2024.

/s/ Thomas R. Califano

Thomas R. Califano